Technology
Health
Biotechnology
Mesoblast
$5.229876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$5.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.05 (0.99%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Mesoblast and other stocks, options, ETFs, and crypto commission-free!
About
Mesoblast Limited American Depositary Shares, also called Mesoblast, is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. Read More The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
Employees
81
Headquarters
Melbourne, Victoria (VIC)
Founded
2004
Market Cap
510.57M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
63.41K
High Today
$5.53
Low Today
$5.15
Open Price
$5.37
Volume
60.32K
52 Week High
$8.78
52 Week Low
$3.35
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
News
Markets InsiderMar 13
Mesoblast Features at Upcoming U.S. Investor Conferences
NEW YORK and MELBOURNE, Australia, March 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it will be featured at two investor conferences in March: Oppenheimer 29th Annual Healthcare Conference in New York on Wednesday, March 20, 2019 at 1:00 p.m. ET. The Alliance for Regenerative Medicine’s Seventh Annual Cell & Gene Therapy Investor Day in New York on Thursday, March 21, 2019 at 4:15 p.m. ET. About Mesoblast Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world...
Simply Wall StMar 10
Before You Buy Mesoblast Limited (ASX:MSB), Consider Its Volatility
If you’re interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio.
MarketBeatMar 10
Stock Price, News, & Analysis for Mesoblast
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing M...
Price Paid on Robinhood
3% Lower
Right Now
52 Week Low
$3.35
Average Price Paid
$5.39
52 Week High
$8.78
Earnings
-$0.26
-$0.18
-$0.10
-$0.02
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Expected May 29, After Hours